Company Profile
Lisata Therapeutics Stock Price, News & Analysis
- Ticker:
- LSTA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.07 USD (-4.46%)
Close
Last updated: August 6, 2026
31.7M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, LSTA closed down 4.46% at $1.07. No new same-company headline was identified in the current news window.
Company overview
Business overview
Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors. Its story is built around the idea that better access to tumors can improve the performance of other anti-cancer approaches.
Geographic Base and Sector Classification
Lisata is headquartered in the United States and listed on NASDAQ, with a small-cap oncology biotechnology profile. It sits in the development-stage cancer and drug-delivery segment.
Business Model Characteristics
The company depends on clinical data, partnership potential, and the ability to prove that its platform can improve outcomes in solid tumors. Investors generally watch trial updates, strategic collaborations, and capital needs.
Position Within the Biotechnology Landscape
Lisata occupies a specialized precision-oncology niche within biotech. The stock is driven by the market's view of whether its delivery-focused strategy can create meaningful clinical differentiation.
Future catalysts
Lisata’s catalysts are certepetide and the pancreatic-cancer / solid-tumor development path, where the next update matters a lot. The company still needs stronger clinical proof.
Recent news
- 01
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Source: Lisata Therapeutics
- 02
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Source: Lisata Therapeutics
- 03
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Source: Lisata Therapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lisata Therapeutics (LSTA)?
Lisata Therapeutics (LSTA) most recently closed at 1.07 USD, a -4.46% move versus the previous session.
What is the market cap of Lisata Therapeutics (LSTA)?
Lisata Therapeutics currently has a market capitalization of 31.7M USD on BioPharmSignal.
What does Lisata Therapeutics do?
Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors. Its story is built around the idea that better access to tumors can improve the performance of other anti-cancer approaches.
On which exchange is LSTA stock listed?
Lisata Therapeutics (LSTA) is associated with NASDAQ, United States, Biopharma.
What is Lisata?
Lisata’s catalysts are certepetide and the pancreatic-cancer / solid-tumor development path, where the next update matters a lot.
Which conditions is Lisata Therapeutics targeting with Lisata?
Lisata Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Lisata Therapeutics describe recent progress with Lisata?
Lisata’s catalysts are certepetide and the pancreatic-cancer / solid-tumor development path, where the next update matters a lot.
What is Therapeutics?
Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors.